Based on our unique expertise in peptides, and with Lyxumia® now selling in the marketplace, we are advancing new innovative me
![Optical appearance and properties of pen injection devices for approved... | Download Scientific Diagram Optical appearance and properties of pen injection devices for approved... | Download Scientific Diagram](https://www.researchgate.net/publication/346228283/figure/fig2/AS:961834261676033@1606330566243/Optical-appearance-and-properties-of-pen-injection-devices-for-approved-GLP-1-receptor_Q640.jpg)
Optical appearance and properties of pen injection devices for approved... | Download Scientific Diagram
![Sanofi India expands diabetes portfolio, launches two diabetes drugs in India | Indiablooms - First Portal on Digital News Management Sanofi India expands diabetes portfolio, launches two diabetes drugs in India | Indiablooms - First Portal on Digital News Management](https://www.indiablooms.com/health_pic/2016/12-1468918157.jpg)
Sanofi India expands diabetes portfolio, launches two diabetes drugs in India | Indiablooms - First Portal on Digital News Management
![An employee assembles an injection-pen for the newly launched diabetes drug Lyxumia at a manufacturing site of French drugmaker Sanofi in Frankfurt June 5, 2013. Sanofi is stepping up the development of An employee assembles an injection-pen for the newly launched diabetes drug Lyxumia at a manufacturing site of French drugmaker Sanofi in Frankfurt June 5, 2013. Sanofi is stepping up the development of](https://c8.alamy.com/comp/2CWM4A3/an-employee-assembles-an-injection-pen-for-the-newly-launched-diabetes-drug-lyxumia-at-a-manufacturing-site-of-french-drugmaker-sanofi-in-frankfurt-june-5-2013-sanofi-is-stepping-up-the-development-of-several-diabetes-treatments-to-get-more-business-in-the-fast-growing-diabetes-business-to-keep-its-no-2-spot-in-the-43-billion-a-year-diabetes-market-sanofi-is-testing-an-improved-version-of-lantus-a-synthetic-insulin-developed-at-the-frankfurt-centre-in-the-1990s-and-currently-sanofis-top-selling-drug-in-late-stage-trials-as-well-as-a-combination-of-the-product-with-lyxumia-a-once-dail-2CWM4A3.jpg)